Killing of Staphylococcus aureus persisters by a multitarget natural product chrysomycin A

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Biochemistry

Background:

• Staphylococcus aureus is a major cause of healthcare- and community-acquired infections.
• Antibiotic resistance, particularly in S. aureus biofilms and persister cells, necessitates new therapeutic strategies.
• Novel antimicrobial agents with unique modes of action are urgently needed.

Purpose of the Study:

• To investigate the antimicrobial potential of chrysomycin A (ChryA) against Staphylococcus aureus.
• To elucidate the mode of action of ChryA against S. aureus biofilms and persister cells.
• To evaluate the efficacy of ChryA in vitro and in vivo.

Main Methods:

• Genetic and biochemical assays were employed to determine ChryA's molecular targets.
• In vitro experiments assessed ChryA's activity against S. aureus biofilms and persister cells.
• In vivo studies evaluated ChryA's killing efficacy.

Main Results:

• Chrysomycin A (ChryA) demonstrated rapid bactericidal activity against S. aureus persisters.
• ChryA effectively eradicated S. aureus biofilms in vitro and showed sustained efficacy in vivo.
• ChryA directly binds to and inhibits GlmU and DapD, key enzymes in peptidoglycan and lysine biosynthesis, by competing with acetyl-CoA.

Conclusions:

• Chrysomycin A represents a promising therapeutic candidate for treating persistent Staphylococcus aureus infections.
• The multi-target mechanism of ChryA, inhibiting essential biosynthetic pathways, offers a potent strategy against antibiotic-tolerant bacteria.
• This study highlights a novel antimicrobial approach combining multiple modes of action in a single molecule.